Login to Your Account

Uni-Bio's osteoporosis candidate achieves phase III endpoint

By Shannon Ellis
Staff Writer

Wednesday, July 2, 2014
SHANGHAI – Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in post-menopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription